Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: Up-regulation of Complement C3 and alpha-2-HS-glycoprotein

Pancreatology

Volumn 13, Issue 3, 2013, Pages 290-297

  Chen, Jiong ^a   Wu, Wen ^a   Chen, Longjiang ^a   Zhou, Hangcheng ^a   Yang, Renbao ^a   Hu, Liwei ^a   Zhao, Yue ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

AHSG; Alpha 2 HS glycoprotein; Complement C3; Diagnosis; Pancreatic ductal adenocarcinoma; Proteomics; Tumor marker

Indexed keywords

COMPLEMENT COMPONENT C3; FETUIN A; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

EID: 84884675157     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2013.03.010     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol 2012;23:1044-52.
3. Willett CG, Daly WJ, Warshaw AL. CA 19-9 is anindex of response toneoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 1996;172:350-2.
4. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-70.
5. Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009;198:333-9.
6. Grønborg M, Bunkenborg J, Kristiansen TZ, Jensen ON, Yeo CJ, Hruban RH, et al. Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 2004;3:1042-55.
7. Cecconi D, Palmieri M, Donadelli M. Proteomics in pancreatic cancer research. Proteomics 2011;11:816-28.
8. Zamò A, Cecconi D. Proteomic analysis of lymphoid and haematopoietic neoplasms: there's more than biomarker discovery. J Proteomics 2010;73:508-20.
9. Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, et al. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res 2011;10:2359-76.
10. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res 2009;15:3812-9.
11. Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, et al. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2011;20:160-71.
12. Rong Y, Jin D, Hou C, Hu J, Wu W, Ni X, et al. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol 2010;10:68-76.
13. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, et al. A novel experimental design for comparative two-dimensional gel analysis: twodimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3:36-44.
14. Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32.
15. Guo X, Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas 2005;31:13-22.
16. Janes Jr RH, Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell JH, et al. National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg 1996;223:261-72.
17. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer 2010;9:149-53.
18. Wang Y, Kuramitsu Y, Ueno T, Suzuki N, Yoshino S, Iizuka N, et al. Differential expression of up-regulated cofilin-1 and down-regulated cofilin-2 characteristic of pancreatic cancer tissues. Oncol Rep 2011;26:1595-9.
19. Walport MJ. Complement. First of two parts. N Engl JMEd 2001;344:1058-66.
20. Walport MJ. Complement. Second of two parts.N Engl J Med 2001;344:1140-4.
21. Hugli TE. Structure and function of the anaphylatoxin. Springer Semin Immunopathol 1984;7:193-219.
22. Scholz W, Mcclurg MR, Cardenas GJ, Smith M, Noonan DJ, Hugli TE, et al. C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol 1990;57:297-307.
23. Andoh A, Fujiyama Y, Sumiyoshi K, Bamba T. Local secretion of complement C3 in the exocrine pancreas: ductal epithelial cells as a possible biosynthetic site. Gastroenterology 1996;110:1919-25.
24. Szalai AJ, van Ginkel FW, Wang Y, McGhee JR, Volanakis JE. Complementdependent acute-phase expression of C-reactive protein and serum amyloid P-component. J Immunol 2000;165:1030-5.
25. Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy:resolving the confusion. Kidney Int 2012;81:434-41.
26. Yuan Y, Ren J, Cao S, Zhang W, Li J. Exogenous C3 protein enhances the adaptive immune response to polymicrobial sepsis through down-regulation of regulatory T cells. Int Immunopharmacol 2012;12:271-7.
27. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K, et al. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol 2012;188:1469-78.
28. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
29. Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in breast cancer. Am J Pathol 1992;140:1039-43.
30. Ajona D, Castano Z, Garayoa M, Zudaire E, Pajares MJ, Martinez A, et al. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 2004;64:6310-8.
31. Ytting H, Jensenius JC, Christensen IJ, Thiel S, Nielsen HJ. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol 2004;39:674-9.
32. Gelderman KA, Hakulinen J, Hagenaars M, Kuppen PJ, Meri S, Gorter A. Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model. Mol Immunol B 2003;40:13-23.
33. Habermann JK, Roblick UJ, Luke BT, Prieto DA, Finlay WJ, Podust VN, et al. Increased serum levels of complement C3 anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 2006;131:1020-9.
34. Märten A, Büchler MW, Werft W, Wente MN, Kirschfink M, Schmidt J. Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology. J Immunother 2010;33:219-24.
35. Mori K, Emoto M, Inaba M. Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discov 2011;5:124-46.
36. Jiang H, Lei SF, Xiao SM, Chen Y, Sun X, Yang F, et al. Association and linkage analysis of COL1A1 and AHSG gene polymorphisms with femoral neck bone geometric parameters in both Caucasian and Chinese nuclear families. Acta Pharmacol Sin 2007;28:375-81.
37. Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ, et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg 2009;208:970-80.
38. Yi JK, Chang JW, Han W, Lee JW, Ko E, Kim DH, et al. Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis. Cancer Epidemiol Biomarkers Prev 2009;18:1357-64.
39. Valle A, Sastre-Serra J, Pol C, Miró AM, Oliver J, Roca P. Proteomic analysis of MCF-7 breast cancer cell line exposed to leptin. Anal Cell Pathol (Amst) 2011;34:147-57.